Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.55 Analyst target: $5.55 Upside: 258.06%
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
See the full interactive analysis & chart →Informational only — not investment advice.